Mai Capital Management Immunity Bio, Inc. Transaction History
Mai Capital Management
- $13 Billion
- Q1 2025
A detailed history of Mai Capital Management transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Mai Capital Management holds 348 shares of IBRX stock, worth $1,009. This represents 0.0% of its overall portfolio holdings.
Number of Shares
348
Previous 348
-0.0%
Holding current value
$1,009
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding IBRX
# of Institutions
239Shares Held
79.9MCall Options Held
1.08MPut Options Held
2.73M-
Vanguard Group Inc Valley Forge, PA20.3MShares$59 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$33.1 Million0.0% of portfolio
-
State Street Corp Boston, MA7.58MShares$22 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA4.29MShares$12.4 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.45MShares$9.99 Million0.07% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.16B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...